Cargando…

Metoprolol‐pridopidine drug–drug interaction and food effect assessments of pridopidine, a new drug for treatment of Huntington's disease

AIMS: Pridopidine is an oral drug in clinical development for treatment of patients with Huntington's disease. This study examined the interactions of pridopidine with in vitro cytochrome P450 activity and characterized the effects of pridopidine on CYP2D6 activity in healthy volunteers using m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rabinovich‐Guilatt, Laura, Steiner, Lilach, Hallak, Hussein, Pastino, Gina, Muglia, Pierandrea, Spiegelstein, Ofer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Drug Interactions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595947/ https://www.ncbi.nlm.nih.gov/pubmed/28449367 http://dx.doi.org/10.1111/bcp.13317

Ejemplares similares

The effect of mild and moderate renal impairment on the pharmacokinetics of pridopidine, a new drug for Huntington's disease
por: Rabinovich‐Guilatt, L., et al.
Publicado: (2015)

Pridopidine activates neuroprotective pathways impaired in Huntington Disease
por: Geva, Michal, et al.
Publicado: (2016)

Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington’s Disease
por: Waters, Susanna, et al.
Publicado: (2018)

Profile of pridopidine and its potential in the treatment of Huntington disease: the evidence to date
por: Squitieri, Ferdinando, et al.
Publicado: (2015)

Pridopidine Reverses Phencyclidine-Induced Memory Impairment
por: Sahlholm, Kristoffer, et al.
Publicado: (2018)

Edoxaban drug–drug interactions with ketoconazole, erythromycin, and cyclosporine
por: Parasrampuria, Dolly A., et al.
Publicado: (2016)

Pridopidine Induces Functional Neurorestoration Via the Sigma-1 Receptor in a Mouse Model of Parkinson’s Disease
por: Francardo, Veronica, et al.
Publicado: (2019)

Evaluation of CYP3A‐mediated drug–drug interactions with romidepsin in patients with advanced cancer
por: Laille, Eric, et al.
Publicado: (2015)

Assessment of Clinical Drug‐Drug Interactions of Elagolix, a Gonadotropin‐Releasing Hormone Receptor Antagonist
por: Polepally, Akshanth R., et al.
Publicado: (2020)

CYP‐mediated drug–drug interactions with evacetrapib, an investigational CETP inhibitor: in vitro prediction and clinical outcome
por: Cannady, Ellen A., et al.
Publicado: (2015)

Evaluation of Potential Drug‐Drug Interaction Risk of Pexidartinib With Substrates of Cytochrome P450 and P‐Glycoprotein
por: Zahir, Hamim, et al.
Publicado: (2020)

Assessment of Disease‐Related Therapeutic Protein Drug‐Drug Interaction for Etrolizumab in Patients With Moderately to Severely Active Ulcerative Colitis
por: Wei, Xiaohui, et al.
Publicado: (2016)

Absence of Drug‐Drug Interaction of Anastrozole on Levonorgestrel Delivered Simultaneously by an Intravaginal Ring: Results of a Phase 2 Trial
por: Nave, Rüdiger, et al.
Publicado: (2019)

A Drug‐Drug Interaction Study to Evaluate the Effect of TAS‐303 on CYP3A Activity in the Small Intestine and Liver
por: Kumagai, Yuji, et al.
Publicado: (2020)

Sigma-1 and dopamine D2/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [(18)F] fluspidine and [(18)F] fallypride PET study
por: Grachev, Igor D., et al.
Publicado: (2020)

Pridopidine for the Improvement of Motor Function in Patients With Huntington's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Chen, Shujun, et al.
Publicado: (2021)

Pridopidine Does Not Significantly Prolong the QTc Interval at the Clinically Relevant Therapeutic Dose
por: Darpo, Borje, et al.
Publicado: (2023)

Drug‐Drug Interaction Study to Assess the Effect of Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of the Novel Cereblon Modulator Avadomide (CC‐122) in Healthy Adult Subjects
por: Ogasawara, Ken, et al.
Publicado: (2019)

First reports of adverse drug reactions and drug interactions
Publicado: (2022)

First reports of adverse drug reactions and drug interactions
Publicado: (2022)

Evaluation of the Pharmacokinetic Drug Interaction of Capmatinib With Itraconazole and Rifampicin and Potential Impact on Renal Transporters in Healthy Subjects
por: Cui, Xiaoming, et al.
Publicado: (2022)

Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug‐Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis
por: Gupta, Neeraj, et al.
Publicado: (2017)

Effects of Pridopidine on Functional Capacity in Early-Stage Participants from the PRIDE-HD Study
por: McGarry, Andrew, et al.
Publicado: (2020)

Lack of Impact by SCY‐078, a First‐in‐Class Oral Fungicidal Glucan Synthase Inhibitor, on the Pharmacokinetics of Rosiglitazone, a Substrate for CYP450 2C8, Supports the Low Risk for Clinically Relevant Metabolic Drug‐Drug Interactions
por: Wring, Stephen, et al.
Publicado: (2018)

Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model
por: Squitieri, Ferdinando, et al.
Publicado: (2015)

Use of a cocktail probe to assess potential drug interactions with cytochrome P450 after administration of belatacept, a costimulatory immunomodulator
por: Williams, Daphne, et al.
Publicado: (2016)

Neuroprotection of retinal ganglion cells by the sigma-1 receptor agonist pridopidine in models of experimental glaucoma
por: Geva, Michal, et al.
Publicado: (2021)

Pridopidine modifies disease phenotype in a SOD1 mouse model of amyotrophic lateral sclerosis
por: Estévez‐Silva, Héctor M., et al.
Publicado: (2022)

Adverse drug reactions and interactions: first reports and special situations
Publicado: (2020)

First reports of adverse drug reactions
Publicado: (2022)

First reports of adverse drug reactions
Publicado: (2022)

Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses
por: Sahlholm, Kristoffer, et al.
Publicado: (2015)

Pridopidine Promotes Synaptogenesis and Reduces Spatial Memory Deficits in the Alzheimer’s Disease APP/PS1 Mouse Model
por: Estévez-Silva, Héctor M., et al.
Publicado: (2022)

Impact of perampanel on pharmacokinetics of concomitant antiepileptics in patients with partial‐onset seizures: pooled analysis of clinical trials
por: Majid, Oneeb, et al.
Publicado: (2016)

Nucleoporin POM121 signals TFEB-mediated autophagy via activation of SIGMAR1/sigma-1 receptor chaperone by pridopidine
por: Wang, Shao-Ming, et al.
Publicado: (2022)

Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse
por: Kusko, Rebecca, et al.
Publicado: (2018)

Rivaroxaban compared with standard thromboprophylaxis after major orthopaedic surgery: co‐medication interactions
por: Kreutz, Reinhold, et al.
Publicado: (2016)

Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications
por: Marra, Fiona, et al.
Publicado: (2018)

Targeting the Sigma-1 Receptor via Pridopidine Ameliorates Central Features of ALS Pathology in a SOD1(G93A) Model
por: Ionescu, Ariel, et al.
Publicado: (2019)

An open-label study to estimate the effect of steady-state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function
por: Moore, Kenneth T, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_qur7dj1cit74odr2u3t9npn30f